GlaxoSmithKline: EU Grants Variation To Tyverb Conditional Marketing Approval

23rd Jun 2010 10:07

LONDON (Dow Jones)--GlaxoSmithKline PLC (GSK.LN) Wednesday confirmed that the European Commission (EC) has granted a variation to the conditional marketing authorization for Tyverb (lapatinib) in the European Union for a new therapeutic indication. MAIN FACTS: -Tyverb, in combination with an aromatase inhibitor, is indicated for the treatment of post-menopausal women with hormone receptor-positive, HER2 (ErbB2) over-expressing metastatic breast cancer and for whom chemotherapy is currently not intended. -The patients in the registration study were not previously treated with trastuzumab or an aromatase inhibitor. -Shares at 0907 GMT down 15.0 pence, or 1.2%, at 1174.5 pence. -By Iain Packham, Dow Jones Newswires; 44-20-7842-9269; [email protected] (END) Dow Jones Newswires June 23, 2010 05:07 ET (09:07 GMT)